SE9904508D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE9904508D0
SE9904508D0 SE9904508A SE9904508A SE9904508D0 SE 9904508 D0 SE9904508 D0 SE 9904508D0 SE 9904508 A SE9904508 A SE 9904508A SE 9904508 A SE9904508 A SE 9904508A SE 9904508 D0 SE9904508 D0 SE 9904508D0
Authority
SE
Sweden
Prior art keywords
new compounds
active compounds
compounds
solvates
stereoisomers
Prior art date
Application number
SE9904508A
Other languages
English (en)
Swedish (sv)
Inventor
Thomas Elebring
Peter Guzzo
Anders Holmen
Thomas Olsson
Marianne Swanson
Sverker Von Unge
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9904508A priority Critical patent/SE9904508D0/xx
Publication of SE9904508D0 publication Critical patent/SE9904508D0/xx
Priority to UA2002064507A priority patent/UA71649C2/uk
Priority claimed from SE0003640A external-priority patent/SE0003640D0/xx
Priority to TW089125135A priority patent/TWI228510B/zh
Priority to CZ20021983A priority patent/CZ20021983A3/cs
Priority to ES00983634T priority patent/ES2230174T3/es
Priority to PT00983634T priority patent/PT1240172E/pt
Priority to SI200030561T priority patent/SI1240172T1/xx
Priority to KR1020027007355A priority patent/KR100689144B1/ko
Priority to EEP200200286A priority patent/EE05067B1/xx
Priority to PL364795A priority patent/PL201789B1/pl
Priority to HK03100457.3A priority patent/HK1048321B/en
Priority to MXPA02005536A priority patent/MXPA02005536A/es
Priority to SK764-2002A priority patent/SK286904B6/sk
Priority to HK03105473.2A priority patent/HK1053125B/xx
Priority to ARP000106418A priority patent/AR030541A1/es
Priority to DE60015796T priority patent/DE60015796T2/de
Priority to EP00983634A priority patent/EP1240172B1/en
Priority to BR0016253-1A priority patent/BR0016253A/pt
Priority to NZ519376A priority patent/NZ519376A/en
Priority to CA2397583A priority patent/CA2397583C/en
Priority to CNB008168989A priority patent/CN1198832C/zh
Priority to JP2001543550A priority patent/JP3914435B2/ja
Priority to RU2002113909/04A priority patent/RU2260595C2/ru
Priority to AT00983634T priority patent/ATE282043T1/de
Priority to HU0300301A priority patent/HUP0300301A3/hu
Priority to US09/786,219 priority patent/US6576626B2/en
Priority to IL14984000A priority patent/IL149840A0/xx
Priority to DK00983634T priority patent/DK1240172T3/da
Priority to PCT/SE2000/002426 priority patent/WO2001042252A1/en
Priority to AU20364/01A priority patent/AU780459B2/en
Priority to EP04021533A priority patent/EP1484333A1/en
Priority to MYPI20005746A priority patent/MY125414A/en
Priority to ZA200204127A priority patent/ZA200204127B/xx
Priority to IS6408A priority patent/IS2231B/is
Priority to NO20022728A priority patent/NO329595B1/no
Priority to US10/406,838 priority patent/US6841698B2/en
Priority to IL149840A priority patent/IL149840A/en
Priority to US11/016,543 priority patent/US7034176B2/en
Priority to US11/300,195 priority patent/US7319095B2/en
Priority to US11/400,021 priority patent/US7807658B2/en
Priority to JP2006175983A priority patent/JP2006306885A/ja
Priority to US11/776,648 priority patent/US20080146836A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/48—Phosphonous acids [RP(OH)2] including [RHP(=O)(OH)]; Thiophosphonous acids including [RP(SH)2], [RHP(=S)(SH)]; Derivatives thereof
    • C07F9/4808—Phosphonous acids [RP(OH)2] including [RHP(=O)(OH)]; Thiophosphonous acids including [RP(SH)2], [RHP(=S)(SH)]; Derivatives thereof the acid moiety containing a substituent or structure which is considered as characteristic
    • C07F9/4816—Acyclic saturated acids or derivatices which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE9904508A 1999-12-09 1999-12-09 New compounds SE9904508D0 (sv)

Priority Applications (42)

Application Number Priority Date Filing Date Title
SE9904508A SE9904508D0 (sv) 1999-12-09 1999-12-09 New compounds
UA2002064507A UA71649C2 (en) 1999-12-09 2000-04-12 Aminopropylphosphinic acids and pharmaceutical composition based thereon
TW089125135A TWI228510B (en) 1999-12-09 2000-11-27 New aminopropylphosphonous acids
AU20364/01A AU780459B2 (en) 1999-12-09 2000-12-04 New aminopropylphosphinic acids
EP04021533A EP1484333A1 (en) 1999-12-09 2000-12-04 New aminopropylphosphonous acids
CA2397583A CA2397583C (en) 1999-12-09 2000-12-04 New aminopropylphosphinic acids
RU2002113909/04A RU2260595C2 (ru) 1999-12-09 2000-12-04 Новые аминопропилфосфиновые кислоты
PT00983634T PT1240172E (pt) 1999-12-09 2000-12-04 Novos acidos aminopropilfosfinicos
SI200030561T SI1240172T1 (en) 1999-12-09 2000-12-04 New aminopropylphosphinic acids
KR1020027007355A KR100689144B1 (ko) 1999-12-09 2000-12-04 신규 아미노프로필포스핀산
EEP200200286A EE05067B1 (et) 1999-12-09 2000-12-04 Aminoproplfosfiinhapped ning nende kasutamine meditsiinis
PL364795A PL201789B1 (pl) 1999-12-09 2000-12-04 Kwasy aminopropylofosfinowe, ich zastosowanie i środek farmaceutyczny
HK03100457.3A HK1048321B (en) 1999-12-09 2000-12-04 New aminopropyl phosphinic acid
MXPA02005536A MXPA02005536A (es) 1999-12-09 2000-12-04 Acidos aminopropilfosfinicos novedosos.
SK764-2002A SK286904B6 (sk) 1999-12-09 2000-12-04 Aminopropylfosfínové kyseliny, ich použitie a farmaceutické prípravky s ich obsahom
HK03105473.2A HK1053125B (en) 1999-12-09 2000-12-04 New aminopropylphosphinic acids
ARP000106418A AR030541A1 (es) 1999-12-09 2000-12-04 Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica
DE60015796T DE60015796T2 (de) 1999-12-09 2000-12-04 Neue aminopropylphosphinsäuren
EP00983634A EP1240172B1 (en) 1999-12-09 2000-12-04 New aminopropylphosphinic acids
BR0016253-1A BR0016253A (pt) 1999-12-09 2000-12-04 Composto, uso de um composto, métodos para a inibição dos relaxamentos do esfìncter esofágico inferior transientes para o tratamento da doença do refluxo gastroesofágico, da regurgitação em bebês, de nocicepção, êmese. dispepsia, ibs, soluções, adicção em cocaìna, dor, tosse, eructação, asma relacionados ou não com gord, formulação farmacêutica, e, processo para a preparação de um composto
NZ519376A NZ519376A (en) 1999-12-09 2000-12-04 New aminopropylphosphinic acids
CZ20021983A CZ20021983A3 (cs) 1999-12-09 2000-12-04 Nové aminopropylfosfinové kyseliny
CNB008168989A CN1198832C (zh) 1999-12-09 2000-12-04 新的氨基丙基次膦酸
JP2001543550A JP3914435B2 (ja) 1999-12-09 2000-12-04 新規なアミノプロピルホスフィン酸
ES00983634T ES2230174T3 (es) 1999-12-09 2000-12-04 Nuevos acidos aminopropilfosfinicos.
AT00983634T ATE282043T1 (de) 1999-12-09 2000-12-04 Neue aminopropylphosphinsäuren
HU0300301A HUP0300301A3 (en) 1999-12-09 2000-12-04 New aminopropylphosphinic acids
US09/786,219 US6576626B2 (en) 1999-12-09 2000-12-04 Aminopropylphosphinic acids
IL14984000A IL149840A0 (en) 1999-12-09 2000-12-04 New aminopropylphosphinic acids
DK00983634T DK1240172T3 (da) 1999-12-09 2000-12-04 Nye aminopropylphosphinsyrer
PCT/SE2000/002426 WO2001042252A1 (en) 1999-12-09 2000-12-04 New aminopropylphosphinic acids
MYPI20005746A MY125414A (en) 1999-12-09 2000-12-07 Aminopropylphosphinic acids
ZA200204127A ZA200204127B (en) 1999-12-09 2002-05-23 New aminopropylphosphinic acids.
IS6408A IS2231B (is) 1999-12-09 2002-06-06 Nýjar amínóprópýlfosfínsýrur
NO20022728A NO329595B1 (no) 1999-12-09 2002-06-07 Nye aminopropylfosfinsyrer, farmasoytiske formuleringer inneholdende slike, samt mellomprodukter til fremstilling av slike
US10/406,838 US6841698B2 (en) 1999-12-09 2003-04-04 Aminopropylphosphinic acids
IL149840A IL149840A (en) 1999-12-09 2004-01-01 Aminopropylphosphinic acids
US11/016,543 US7034176B2 (en) 1999-12-09 2004-12-16 Aminopropylphosphinic acids
US11/300,195 US7319095B2 (en) 1999-12-09 2005-12-13 Use of GABAB receptor agonists
US11/400,021 US7807658B2 (en) 1999-12-09 2006-04-07 Use of GabaB receptor agonists
JP2006175983A JP2006306885A (ja) 1999-12-09 2006-06-27 新規なアミノプロピルホスフィン酸
US11/776,648 US20080146836A1 (en) 1999-12-09 2007-07-12 New Aminopropylphosphinic acids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904508A SE9904508D0 (sv) 1999-12-09 1999-12-09 New compounds
SE0003640A SE0003640D0 (sv) 2000-10-09 2000-10-09 New compounds

Publications (1)

Publication Number Publication Date
SE9904508D0 true SE9904508D0 (sv) 1999-12-09

Family

ID=26655259

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9904508A SE9904508D0 (sv) 1999-12-09 1999-12-09 New compounds

Country Status (33)

Country Link
US (5) US6576626B2 (OSRAM)
EP (2) EP1240172B1 (OSRAM)
JP (2) JP3914435B2 (OSRAM)
KR (1) KR100689144B1 (OSRAM)
CN (1) CN1198832C (OSRAM)
AR (1) AR030541A1 (OSRAM)
AT (1) ATE282043T1 (OSRAM)
AU (1) AU780459B2 (OSRAM)
BR (1) BR0016253A (OSRAM)
CA (1) CA2397583C (OSRAM)
CZ (1) CZ20021983A3 (OSRAM)
DE (1) DE60015796T2 (OSRAM)
DK (1) DK1240172T3 (OSRAM)
EE (1) EE05067B1 (OSRAM)
ES (1) ES2230174T3 (OSRAM)
HK (1) HK1048321B (OSRAM)
HU (1) HUP0300301A3 (OSRAM)
IL (2) IL149840A0 (OSRAM)
IS (1) IS2231B (OSRAM)
MX (1) MXPA02005536A (OSRAM)
MY (1) MY125414A (OSRAM)
NO (1) NO329595B1 (OSRAM)
NZ (1) NZ519376A (OSRAM)
PL (1) PL201789B1 (OSRAM)
PT (1) PT1240172E (OSRAM)
RU (1) RU2260595C2 (OSRAM)
SE (1) SE9904508D0 (OSRAM)
SI (1) SI1240172T1 (OSRAM)
SK (1) SK286904B6 (OSRAM)
TW (1) TWI228510B (OSRAM)
UA (1) UA71649C2 (OSRAM)
WO (1) WO2001042252A1 (OSRAM)
ZA (1) ZA200204127B (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
US7319095B2 (en) * 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
US20040063684A1 (en) * 2001-02-05 2004-04-01 Kamm Michael A. Treatment of oesophageal motility disorders and gastro-oesophageal reflux disease
AR033779A1 (es) * 2001-06-08 2004-01-07 Astrazeneca Ab Compuestos utiles en la enfermedad de reflujo
SE0201939D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination
SE0201940D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
SE0402462D0 (sv) * 2004-10-08 2004-10-08 Astrazeneca Ab New process
WO2006050471A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
US20060160777A1 (en) * 2004-12-27 2006-07-20 Anders Lehmann New use of GABAbeta receptor agonists
JP2009521430A (ja) 2005-12-23 2009-06-04 アストラゼネカ・アクチエボラーグ Ｇａｂａ−ｂ受容体モジュレーター
EP1966154A4 (en) 2005-12-23 2011-01-26 Astrazeneca Ab IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
US7585996B2 (en) 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
ES2373255T3 (es) * 2007-05-04 2012-02-01 Astrazeneca Ab Proceso para s�?ntesis de �?cidos alquilfosf�?nicos mediante iniciación de una amina y un aminóxido.
JP2010534239A (ja) * 2007-07-25 2010-11-04 アストラゼネカ・アクチエボラーグ Ｎｅｒｄの治療のための（３−アミノ−２−フルオロプロピル）ホスフィン酸の使用
WO2009082344A1 (en) * 2007-12-21 2009-07-02 Astrazeneca Ab Novel process for making (2r)-(3-amino-2-fluoropropyl)phosphinic acid form a
EP2235027A4 (en) * 2007-12-21 2011-06-22 Astrazeneca Ab NEW CRYSTALLINE FORM OF (2R) - (3-AMINO-2-FLUOROPROPYL) PHOSPHINIC ACID
WO2009082348A1 (en) * 2007-12-21 2009-07-02 Astrazeneca Ab Novel crystalline form c of (2r)-(3-amino-2-fluoropropyl)phosphinic acid
WO2009145716A1 (en) * 2008-05-28 2009-12-03 Astrazeneca Ab New pharmaceutical formulation useful in gerd therapy
CN102177164B (zh) 2008-11-05 2015-02-11 科莱恩金融(Bvi)有限公司 利用烯丙醇/丙烯醛制备二烷基次膦酸、二烷基次膦酸酯和二烷基次膦酸盐的方法,以及它们的用途
EP2352740B1 (de) 2008-11-07 2014-09-24 Clariant Finance (BVI) Limited Verfahren zur herstellung von dialkylphosphinsäuren, -estern und -salzen mittels acrylsäurederivaten und ihre verwendung
DE102008056341A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von monoaminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
JP5743219B2 (ja) 2008-11-11 2015-07-01 クラリアント・ファイナンス・（ビーブイアイ）・リミテッド アリル化合物を用いる、モノアリル官能性ジアルキルホスフィン酸、それらの塩およびエステルの製造方法およびそれらの使用
DE102008060035A1 (de) 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060535A1 (de) 2008-12-04 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylether und ihre Verwendung
DE102008063668A1 (de) 2008-12-18 2010-07-01 Clariant International Limited Verfahren zur Herstellung von Alkylphosponsäuren, -estern und -salzen mittels Oxidation von Alkylphosphonigsäuren und ihre Verwendung
KR101697948B1 (ko) 2008-12-18 2017-01-19 클라리언트 파이넌스 (비브이아이)리미티드 아세틸렌을 사용하는 에틸렌디알킬포스핀산, 에틸렌디알킬포스핀산 에스테르 및 에틸렌디알킬포스핀산 염의 제조방법 및 이의 용도
DE102008063642A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monocarboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Alkylenoxiden und ihre Verwendung
DE102008063627A1 (de) * 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monohydroxyfunktionalisierten Dialkylphosphinsäuren,-estern und -salzen mittels Ethylenoxid und ihre Verwendung
DE102008064003A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449046A (de) 1963-07-09 1967-12-31 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
GB8425872D0 (en) * 1984-10-12 1984-11-21 Ciba Geigy Ag Chemical compounds
WO1987004077A1 (en) 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
US4740332A (en) * 1986-05-12 1988-04-26 E. R. Squibb & Sons, Inc. Process for preparing phosphonous acids
GB8820266D0 (en) * 1988-08-26 1988-09-28 Smith Kline French Lab Compounds
US5281747A (en) 1989-05-13 1994-01-25 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
GB8911017D0 (en) 1989-05-13 1989-06-28 Ciba Geigy Ag Substituted aminoalkylphosphinic acids
US5567840A (en) 1989-05-13 1996-10-22 Ciba-Geigy Corporation Substituted aminoalkylphosphinic acids
US5006560A (en) 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
IL114631A (en) * 1990-06-22 1998-12-06 Novartis Ag Anti-epileptic compositions containing gabab- antagonistic compounds
FR2663934B1 (fr) 1990-06-27 1994-06-03 Adir Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
GB9125615D0 (en) * 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
AU662404B2 (en) * 1992-05-08 1995-08-31 Novartis Ag Novel N-aralkyl- and N-heteroaralkyl-aminoalkanephosphinic acids
FR2722192A1 (fr) 1994-07-06 1996-01-12 Adir Nouveaux derives de l'acide 4-amino butyrique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9420784D0 (en) 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
SE9603408D0 (sv) 1996-09-18 1996-09-18 Astra Ab Medical use
SE9904507D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
US7319095B2 (en) * 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds

Also Published As

Publication number Publication date
AU780459B2 (en) 2005-03-24
WO2001042252A1 (en) 2001-06-14
AU2036401A (en) 2001-06-18
UA71649C2 (en) 2004-12-15
US20070021393A1 (en) 2007-01-25
CN1409716A (zh) 2003-04-09
HUP0300301A2 (hu) 2003-06-28
JP3914435B2 (ja) 2007-05-16
JP2003516407A (ja) 2003-05-13
NO20022728L (no) 2002-08-07
EP1240172A1 (en) 2002-09-18
HK1053125A1 (en) 2003-10-10
AR030541A1 (es) 2003-08-27
HK1048321B (en) 2005-09-30
EP1240172B1 (en) 2004-11-10
ATE282043T1 (de) 2004-11-15
RU2260595C2 (ru) 2005-09-20
US6576626B2 (en) 2003-06-10
ZA200204127B (en) 2003-08-25
CN1198832C (zh) 2005-04-27
CZ20021983A3 (cs) 2002-11-13
TWI228510B (en) 2005-03-01
IL149840A0 (en) 2002-11-10
EP1484333A1 (en) 2004-12-08
BR0016253A (pt) 2002-08-27
US20050137414A1 (en) 2005-06-23
US20030220303A1 (en) 2003-11-27
KR20020060992A (ko) 2002-07-19
SK7642002A3 (en) 2002-12-03
US7807658B2 (en) 2010-10-05
NO329595B1 (no) 2010-11-22
PL201789B1 (pl) 2009-05-29
US6841698B2 (en) 2005-01-11
SK286904B6 (sk) 2009-07-06
IS6408A (is) 2002-06-06
CA2397583A1 (en) 2001-06-14
CA2397583C (en) 2010-11-09
MY125414A (en) 2006-07-31
EE05067B1 (et) 2008-08-15
DE60015796D1 (de) 2004-12-16
KR100689144B1 (ko) 2007-03-08
PT1240172E (pt) 2005-02-28
US20080146836A1 (en) 2008-06-19
US7034176B2 (en) 2006-04-25
EE200200286A (et) 2003-08-15
NZ519376A (en) 2003-11-28
JP2006306885A (ja) 2006-11-09
PL364795A1 (en) 2004-12-13
ES2230174T3 (es) 2005-05-01
MXPA02005536A (es) 2004-09-10
RU2002113909A (ru) 2004-01-10
SI1240172T1 (en) 2005-02-28
IS2231B (is) 2007-04-15
US20020156053A1 (en) 2002-10-24
DE60015796T2 (de) 2005-11-03
HUP0300301A3 (en) 2008-12-29
DK1240172T3 (da) 2005-02-14
HK1048321A1 (en) 2003-03-28
NO20022728D0 (no) 2002-06-07
IL149840A (en) 2006-04-10

Similar Documents

Publication Publication Date Title
SE9904508D0 (sv) New compounds
AUPR213700A0 (en) Antiviral agents
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
PT1029853E (pt) Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos
SE9903544D0 (sv) Novel compounds
SE0102055D0 (sv) New Compounds
BR9805734A (pt) Derivados de imidazolin-4-ona úteis como agentes anticancerìgenos.
SE0100569D0 (sv) New compounds
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
PT992509E (pt) Novos derivados macrolidos
SE0102440D0 (sv) New compound
SE9904507D0 (sv) New compounds
TW200606164A (en) New compounds
GR3019274T3 (en) Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazine-4-ones, their preparation and their therapeutical use
DE60107832D1 (en) Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
SE0102057D0 (sv) New Salts I
SE0102058D0 (sv) New Salts II
SE9900190D0 (sv) New compounds
DE60227113D1 (de) Kondensierte camptothecine als antitumormittel
BR9902049A (pt) Derivados 9a,11b-desidro de 9-oxima-3-ceto-6-o-metileritromicina.
MY128457A (en) 2-aminocarbonyl-9h-purine derivatives
ATE268768T1 (de) Antithrombosemittel
MY135855A (en) "pyrrolopyrimidinone derivatives, process of preparation and use"